[CAS NO. 1357171-62-0] ML228
PRODUCTS SPECIFICATIONS [1357171-62-0]
DESCRIPTION [1357171-62-0]
Overview
| MDL | MFCD26792570 |
|---|---|
| Molecular Weight | 415.49 |
| Molecular Formula | C27H21N5 |
| SMILES | C1(C2=NC=CC=C2)=NC(NCC3=CC=C(C4=CC=CC=C4)C=C3)=C(C5=CC=CC=C5)N=N1 |
4 Publications Citing Use of MCE
Summary
IC50 & Target
EC50: 1 μM (HIF) [1]
In Vitro
ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications [1] [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | SD rat [3] |
| Dosage: | 1 µg/kg |
| Administration: | injection; 7 days |
| Result: | Alleviated SCI of the central nervous system and relieve associated symptoms. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 35 mg/mL ( 84.24 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4068 mL | 12.0340 mL | 24.0680 mL |
| 5 mM | 0.4814 mL | 2.4068 mL | 4.8136 mL |
| 10 mM | 0.2407 mL | 1.2034 mL | 2.4068 mL |
References
- [1] Theriault JR, et al. Discovery of a Small Molecule Activator of the Hypoxia Inducible Factor Pathway. Probe Reports from the NIH Molecular Libraries Program.
- [2] Theriault JR, et al. Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012 Jan 1;22(1):76-81.
- [3] Chen H, et al. Effect of hypoxia-inducible factor-1/vascular endothelial growth factor signaling pathway on spinal cord injury in rats.Exp Ther Med. 2017 Mar;13(3):861-866.
